CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics Inc. (“APRINOIA” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision ...
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy Fast Track Designation follows announcement in January 2024 ...
CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“Aprinoia” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and precision ...
(MENAFN- GlobeNewsWire - Nasdaq) Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a“Study May Proceed” letter for Aprinoia's planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results